# OnCo record relmacabtagene-autoleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/relmacabtagene-autoleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "relmacabtagene-autoleucel" ;
  schema:name "Relmacabtagene autoleucel"@en ;
  schema:description "Relma-cel was the first CAR-T therapy developed and made in China to be approved, for large B-cell lymphoma that has come back after two treatments."@en ;
  schema:url <https://onco.cc/drugs/relmacabtagene-autoleucel/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.jwtherapeutics.com/en/>, <https://doi.org/10.1002/cam4.3686>, <https://www.nmpa.gov.cn> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Cell therapy (autologous CD19 CAR-T, 4-1BB)" ;
  schema:alternateName "Carteyva" ;
  onco:approval "China 2021: Relapsed or refractory large B-cell lymphoma after two or more lines", "China 2022: Relapsed or refractory follicular lymphoma after two or more lines" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:companies <https://onco.cc/companies/jw-therapeutics/>, <https://onco.cc/companies/wuxi-apptec/> ;
  onco:trials <https://onco.cc/trials/reliance/>, <https://onco.cc/trials/nct06093841/>, <https://onco.cc/trials/nct06479356/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ying-cancer-med/> .